(Q69490707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

title

Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

author name string

C B Pratt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

T J Vietti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

E Etcubanas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

C Sexauer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

R A Krance

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

D H Mahoney

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

R B Patterson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

publication date

1 January 1986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

2 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

page(s)

43-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3700039%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00172015

2 October 2019

exact match

0 references

cites work

Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.

1 reference

12 December 2020

Comparison of Antineoplastic Activity of Aminoethylaminoanthraquinones and Anthracycline Antibiotics

1 reference

12 December 2020

The relative tolerance of children and adults to anticancer drugs

1 reference

12 December 2020

Activity of mitoxantrone in a human tumor cloning system

1 reference

12 December 2020

Evaluation of toxicity: clinical issues

1 reference

12 December 2020

Experimental antitumor activity of aminoanthraquinones

1 reference

12 December 2020

Clinical safety and tolerance of mitoxantrone

1 reference

12 December 2020

Mitoxantrone treatment in advanced breast cancer

1 reference

12 December 2020

Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice

1 reference

12 December 2020

Phase I trial of mitoxantrone in children

1 reference

12 December 2020

A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer

1 reference

12 December 2020

Mitoxantrone in relapsed and refractory acute leukemia

1 reference

12 December 2020

Adriamycin-induced myocardial lesions Report of a Workshop

1 reference

12 December 2020

Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug

1 reference

12 December 2020

Mitoxantrone in the treatment of relapsed and refractory acute leukemia.

1 reference

12 December 2020

Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.

1 reference

12 December 2020

Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia

1 reference

12 December 2020

Mitoxantrone (novantrone): a review of experimental and early clinical studies

1 reference

12 December 2020